Showing posts with label burger. Show all posts
Showing posts with label burger. Show all posts
Friday, April 20, 2012
Medscape: (Avastin) Bevacizumab: First-Line Therapy in Ovarian Cancer?: Evidence for First-Line Therapy Dr's Markman, Burger, Swenterton
Bevacizumab: First-Line Therapy in Ovarian Cancer?: Evidence for First-Line Therapy
Editor’s Note:
Two phase 3 trials published in the New England Journal of Medicine on December 29, 2011, found bevacizumab to be active as first-line therapy in advanced ovarian cancer. Although both trials showed an increase in progression-free survival [PFS], not enough time has elapsed to determine whether the drug extends overall survival. Furthermore, it is unclear whether bevacizumab in ovarian cancer is best used as first-line or second-line therapy. Recently, Drs. Robert Burger and Kenneth Swenerton participated in a Medscape virtual debate via email to address this question: "Should bevacizumab be used as first-line therapy in patients with advanced ovarian cancer?" Dr. Maurie Markman served as moderator. What follows is their conversation......
add your opinions
Avastin
,
Bevacizumab
,
burger
,
first line therapy
,
markman
,
Swenerton
Wednesday, March 09, 2011
ELC : Imedex e-learning center March 8th, 2011 video (30 min) interviews from SGO
Note: requires password/registration to view videos (free), risk factors, hereditary, KRAS mutation/variant (in many other cancers as well), MiRnA, ICON7 (Avastin).....
Featured Activity:
You must be a registered Imedex.com member to access this.Please enter your email address and password.Email Password | ||
Dr Bradley Monk interviews 6 nationally recognized experts in GYN oncology about their interpretations of clinically relevant data presented at the annual meeting. Drs Deborah Armstrong, Barbara Goff, Tom Herzog, Warner Huh, Robert Coleman, and Robert Burger comprise the esteemed faculty.
Subscribe to:
Posts
(
Atom
)